Physician profile
Chad D Johanning
NPI 1083625818
$5,871.25
in general payments reported to CMS, 2019-2025
41 companies · $694 in 2025
The $694 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $786 · 2020: $1,176 · 2021: $1,113 · 2022: $1,091 · 2023: $230 · 2024: $781 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,705.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $639.97 | 2021-2025 | |
| Novo Nordisk INC | $596.41 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $570.67 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $554.47 | 2019-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $421.91 | 2019-2024 | Jardiance |
| Pfizer INC. | $329.79 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $310.68 | 2019-2022 | |
| Watermark Medical, INC. | $275.87 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $213.10 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.78 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $158.28 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $139.68 | 2020-2022 | |
| Glaxosmithkline, LLC. | $138.05 | 2019-2023 | Shingrix |
| Astellas Pharma US INC | $131.08 | 2019-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $125.27 | 2020-2025 | Spravato |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $112.09 | 2021-2024 | Adzenys Xr-Odt |
| Allergan, INC. | $107.35 | 2019-2020 | |
| Mckesson Medical-Surgical, INC. | $100.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $91.76 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $82.45 | 2021-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Amarin Pharma, INC. | $58.50 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $56.38 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $55.42 | 2020-2021 | |
| Sanofi Pasteur INC. | $54.65 | 2022-2025 | |
| Abbott Laboratories | $47.06 | 2021-2022 | |
| Hologic Sales and Service, LLC | $43.47 | 2024-2025 | Thinprep 2000 Processor, Aptima |
| Axsome Therapeutics, INC. | $37.85 | 2023-2024 | Auvelity |
| Covis Pharma Gmbh | $26.90 | 2022 | |
| Esperion Therapeutics, INC. | $23.82 | 2021 | |
| Boston Scientific Corporation | $23.45 | 2025 | Watchman Flx |
| Eisai INC. | $22.25 | 2021 | |
| Seqirus USA INC | $20.54 | 2025 | Fluad, Flucelvax |
| Supernus Pharmaceuticals, INC. | $18.58 | 2022 | |
| Dexcom, INC. | $17.67 | 2024 | Dexcom G6 Transmitter |
| Roche Diagnostics Corporation | $17.33 | 2019 | |
| Ironshore Pharmaceuticals INC. | $17.27 | 2019 | |
| Noven Therapeutics, LLC | $15.96 | 2024 | Xelstrym |
| Sage Therapeutics, LLC | $14.71 | 2019 | |
| Insulet Corporation | $13.98 | 2025 | Omnipod |
| Exact Sciences Corporation | $13.44 | 2023 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $11.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Johanning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.